A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Mecasermin
Motavizumab
The risk or severity of adverse effects can be increased when Motavizumab is combined with Brentuximab vedotin.
Mecasermin
Sonepcizumab
The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Brentuximab vedotin.
Mecasermin
BIIB015
The risk or severity of adverse effects can be increased when BIIB015 is combined with Brentuximab vedotin.
Mecasermin
Clenoliximab
The risk or severity of adverse effects can be increased when Clenoliximab is combined with Brentuximab vedotin.
Mecasermin
Nimotuzumab
The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Brentuximab vedotin.
Mecasermin
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brentuximab vedotin.
Mecasermin
Lumiliximab
The risk or severity of adverse effects can be increased when Lumiliximab is combined with Brentuximab vedotin.
Mecasermin
Eldelumab
The risk or severity of adverse effects can be increased when Eldelumab is combined with Brentuximab vedotin.
Mecasermin
IMC-1C11
The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Brentuximab vedotin.
Mecasermin
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brentuximab vedotin.
Mecasermin
TB-402
The risk or severity of adverse effects can be increased when TB-402 is combined with Brentuximab vedotin.
Mecasermin
IPH 2101
The risk or severity of adverse effects can be increased when IPH 2101 is combined with Brentuximab vedotin.
Mecasermin
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Brentuximab vedotin.
Mecasermin
Glembatumumab vedotin
The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Brentuximab vedotin.
Mecasermin
Leronlimab
The risk or severity of adverse effects can be increased when Leronlimab is combined with Brentuximab vedotin.
Mecasermin
CT-011
The risk or severity of adverse effects can be increased when CT-011 is combined with Brentuximab vedotin.
Mecasermin
MYO-029
The risk or severity of adverse effects can be increased when MYO-029 is combined with Brentuximab vedotin.
Mecasermin
RI 624
The risk or severity of adverse effects can be increased when RI 624 is combined with Brentuximab vedotin.
Mecasermin
TNX-901
The risk or severity of adverse effects can be increased when TNX-901 is combined with Brentuximab vedotin.
Mecasermin
PRO-542
The risk or severity of adverse effects can be increased when PRO-542 is combined with Brentuximab vedotin.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3